Imipenem/Cilastatin/Relebactam + Cefepime + Meropenem + Piperacillin-Tazobactam + Vancomycin + Daptomycin + Linezolid
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic and Lymphoid Cell Neoplasm
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Trial Timeline
Sep 14, 2021 → Oct 6, 2023
NCT ID
NCT04983901About Imipenem/Cilastatin/Relebactam + Cefepime + Meropenem + Piperacillin-Tazobactam + Vancomycin + Daptomycin + Linezolid
Imipenem/Cilastatin/Relebactam + Cefepime + Meropenem + Piperacillin-Tazobactam + Vancomycin + Daptomycin + Linezolid is a phase 2 stage product being developed by Merck for Hematopoietic and Lymphoid Cell Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT04983901. Target conditions include Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm.
What happened to similar drugs?
1 of 3 similar drugs in Hematopoietic and Lymphoid Cell Neoplasm were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04983901 | Phase 2 | Completed |
Competing Products
20 competing products in Hematopoietic and Lymphoid Cell Neoplasm